JCI - Citations to Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV

Citations to this article

Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV

Armanda Casrouge, … , Stanislas Pol, Matthew L. Albert

Armanda Casrouge, … , Stanislas Pol, Matthew L. Albert

Published December 22, 2010
Citation Information: J Clin Invest. 2011;121(1):308-317. https://doi.org/10.1172/JCI40594.

View: Text | PDF

Research Article

Total citations by year

Year:	2024	2023	2022	2021	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	Total
Citations:	2	3	5	5	4	7	5	12	8	6	14	13	4	1	89

Citation information

Citations to this article (89)

Title and authors	Publication	Year
Natural carboxyterminal truncation of human CXCL10 attenuates glycosaminoglycan binding, CXCR3A signaling and lymphocyte chemotaxis, while retaining angiostatic activity. Dillemans L, Yu K, De Zutter A, Noppen S, Gouwy M, Berghmans N, Verhallen L, De Bondt M, Vanbrabant L, Brusselmans S, Martens E, Schols D, Verschueren P, Rosenkilde MM, Marques PE, Struyf S, Proost P	Cell communication and signaling : CCS	2024
The Laws of Attraction: Chemokines as Critical Mediators in Cancer Progression and Immunotherapy Response in Bladder Cancer Hassouneh Z, Kim ME, Bowman N, Rao M, Zhang N, Huang G, Svatek RS, Mukherjee N	Cancers	2024
A review of the pleiotropic actions of the IFN-inducible CXC chemokine receptor 3 ligands in the synovial microenvironment. Dillemans L, De Somer L, Neerinckx B, Proost P	Cellular and molecular life sciences : CMLS	2023
Differential Anti-Tumor Effects of IFN-Inducible Chemokines CXCL9, CXCL10, and CXCL11 on a Mouse Squamous Cell Carcinoma Cell Line Matsumoto A, Hiroi M, Mori K, Yamamoto N, Ohmori Y	Medical Sciences	2023
Unraveling DPP4 Receptor Interactions with SARS-CoV-2 Variants and MERS-CoV: Insights into Pulmonary Disorders via Immunoinformatics and Molecular Dynamics Roy AN, Gupta AM, Banerjee D, Chakrabarti J, Raghavendra PB	Viruses	2023
Does DPP-IV Inhibition Offer New Avenues for Therapeutic Intervention in Malignant Disease? P Busek, J Duke-Cohan, A Sedo	Cancers	2022
Potential Effect of DPP-4 Inhibitors Towards Hepatic Diseases and Associated Glucose Intolerance Sharma A, Virmani T, Sharma A, Chhabra V, Kumar G, Pathak K, Alhalmi A	Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy	2022
Proline-specific peptidase activities (DPP4, PRCP, FAP and PREP) in plasma of hospitalized COVID-19 patients Bracke A, De Hert E, De bruyn M, Claesen K, Vliegen G, Vujkovic A, van Petersen L, De Winter FH, Hotterbeekx A, Brosius I, Theunissen C, Van Ierssel S, van Frankenhuijsen M, Vlieghe E, Vercauteren K, Van der Veken P, Hendriks D, Kumar-Singh S, De Meester I	Clinica chimica acta; international journal of clinical chemistry	2022
CD26/DPP4 as a Therapeutic Target in Nonalcoholic Steatohepatitis Associated Hepatocellular Carcinoma Nishina S, Hino K	Cancers	2022
IP-10 Interferes With the Antiviral Response of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection Wang Y, Hu Y, Zhang X, Luo Y, Ma L, Lu J, Liang Q, Xu C, Zhao C, Pan CQ	Frontiers in public health	2022
Chemokines in the Landscape of Cancer Immunotherapy: How They and Their Receptors Can Be Used to Turn Cold Tumors into Hot Ones? N Karin	Cancers	2021
From ELISA to Immunosorbent Tandem Mass Spectrometry Proteoform Analysis: The Example of CXCL8/Interleukin-8 M Metzemaekers, SA Salama, J Vandooren, A Mortier, R Janssens, S Vandendriessche, E Ganseman, E Martens, M Gouwy, B Neerinckx, P Verschueren, LD Somer, C Wouters, S Struyf, G Opdenakker, JV Damme, P Proost	Frontiers in immunology	2021
DPP4 Inhibitors and COVID-19–Holy Grail or Another Dead End? A Krejner-Bienias, K Grzela, T Grzela	Archivum Immunologiae et Therapiae Experimentalis	2021
Dipeptidyl Peptidase 4 Inhibitors Decrease the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis C Infection and Type 2 Diabetes Mellitus: A Nationwide Study in Taiwan WH Hsu, SP Sue, HL Liang, CW Tseng, HC Lin, WL Wen, MY Lee	Frontiers in public health	2021
DPP4 Inhibitor Sitagliptin Enhances Lymphocyte Recruitment and Prolongs Survival in a Syngeneic Ovarian Cancer Mouse Model AL Wilson, LR Moffitt, KL Wilson, M Bilandzic, MD Wright, MD Gorrell, MK Oehler, M Plebanski, AN Stephens	Cancers	2021
Pathogen Evasion of Chemokine Response Through Suppression of CXCL10 AL Antonia, KD Gibbs, ED Trahair, KJ Pittman, AT Martin, BH Schott, JS Smith, S Rajagopal, JW Thompson, RL Reinhardt, DC Ko	Frontiers in Cellular and Infection Microbiology	2019
IP-10 dried blood spots assay monitoring treatment efficacy in extrapulmonary tuberculosis in a low-resource setting IM Hoel, MD Jørstad, M Marijani, M Ruhwald, T Mustafa, AM Dyrhol-Riise	Scientific Reports	2019
Immunomodulation of CXCL10 Secretion by Hepatitis C Virus: Could CXCL10 Be a Prognostic Marker of Chronic Hepatitis C? SM Ferrari, P Fallahi, I Ruffilli, G Elia, F Ragusa, SR Paparo, A Patrizio, V Mazzi, M Colaci, D Giuggioli, C Ferri, A Antonelli	Journal of Immunology Research	2019
Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell Carcinoma W Xu, M Puligandla, J Manola, AJ Bullock, D Tamasauskas, DF McDermott, MB Atkins, NB Haas, K Flaherty, RG Uzzo, JP Dutcher, RS DiPaola, RS Bhatt	Clinical cancer research	2019
Systemic DPP4 activity is reduced during primary HIV-1 infection and is associated with intestinal RORC + CD4 + cell levels: a surrogate marker candidate of HIV-induced intestinal damage MJ Ploquin, A Casrouge, Y Madec, N Noël, B Jacquelin, N Huot, D Duffy, SP Jochems, L Micci, C Lécuroux, F Boufassa, T Booiman, T Garcia-Tellez, M Ghislain, RL Grand, O Lambotte, N Kootstra, L Meyer, C Goujard, M Paiardini, ML Albert, M Müller-Trutwin	Journal of the International AIDS Society	2018
Overview of the Mechanisms that May Contribute to the Non-Redundant Activities of Interferon-Inducible CXC Chemokine Receptor 3 Ligands M Metzemaekers, V Vanheule, R Janssens, S Struyf, P Proost	Frontiers in immunology	2018
Interplay of DDP4 and IP-10 as a Potential Mechanism for Cell Recruitment to Tuberculosis Lesions T Blauenfeldt, L Petrone, F del Nonno, A Baiocchini, L Falasca, T Chiacchio, V Bondet, V Vanini, F Palmieri, G Galluccio, A Casrouge, J Eugen-Olsen, ML Albert, D Goletti, D Duffy, M Ruhwald	Frontiers in immunology	2018
Lymphocytes are a major source of circulating soluble dipeptidyl peptidase 4: Circulating sDPP4 is derived from lymphocytes A Casrouge, AV Sauer, RB da Silva, M Tejera-Alhambra, S Sánchez-Ramón, ICAReB, C Cancrini, MA Ingersoll, A Aiuti, ML Albert	Clinical & Experimental Immunology	2018
Dipeptidyl Peptidase 4 Inhibitors Reduce Hepatocellular Carcinoma by Activating Lymphocyte Chemotaxis in Mice S Nishina, A Yamauchi, T Kawaguchi, K Kaku, M Goto, K Sasaki, Y Hara, Y Tomiyama, F Kuribayashi, T Torimura, K Hino	CMGH Cellular and Molecular Gastroenterology and Hepatology	2018
Serum IP-10 levels and increased DPPIV activity are linked to circulating CXCR3+ T cells in cholestatic HCV patients M Rau, J Schmitt, T Berg, AE Kremer, B Stieger, K Spanaus, B Bengsch, MR Romero, JJ Marin, V Keitel, H Klinker, HP Tony, B Müllhaupt, A Geier, GD Alpini	PloS one	2018
Immune response biomarkers in human and veterinary research A Llibre, D Duffy	Comparative Immunology, Microbiology and Infectious Diseases	2018
Correction of vitamin D deficiency facilitated suppression of IP-10 and DPP IV levels in patients with chronic hepatitis C: A randomised double-blinded, placebo-control trial P Komolmit, K Charoensuk, K Thanapirom, S Suksawatamnuay, P Thaimai, C Chirathaworn, Y Poovorawan, JF Huang	PloS one	2017
Glycosaminoglycans Regulate CXCR3 Ligands at Distinct Levels: Protection against Processing by Dipeptidyl Peptidase IV/CD26 and Interference with Receptor Signaling M Metzemaekers, A Mortier, R Janssens, D Boff, L Vanbrabant, N Lamoen, JV Damme, M Teixeira, ID Meester, F Amaral, P Proost	International journal of molecular sciences	2017
Inducible protein-10 as a predictive marker of antiviral hepatitis C treatment: A systematic review B Neesgaard, M Ruhwald, N Weis	World journal of hepatology	2017
Pro-Inflammatory CXCR3 Impairs Mitochondrial Function in Experimental Non-Alcoholic Steatohepatitis J Du, X Zhang, J Han, K Man, Y Zhang, ES Chu, Y Nan, J Yu	Theranostics	2017
Biomarkers of Infectious Diseases Jain KK	The Handbook of Biomarkers	2017
Inhibition of DPP4 activity in humans establishes its in vivo role in CXCL10 post‐translational modification: prospective placebo‐controlled clinical studies J Decalf, KV Tarbell, A Casrouge, JD Price, G Linder, E Mottez, P Sultanik, V Mallet, S Pol, D Duffy, ML Albert	EMBO Molecular Medicine	2016
CD26/dipeptidylpeptidase IV-chemokine interactions: double-edged regulation of inflammation and tumor biology A Mortier, M Gouwy, JV Damme, P Proost, S Struyf	Journal of leukocyte biology	2016
Fungal Mimicry of a Mammalian Aminopeptidase Disables Innate Immunity and Promotes Pathogenicity AK Sterkel, JL Lorenzini, JS Fites, K Subramanian Vignesh, TD Sullivan, M Wuthrich, T Brandhorst, N Hernandez-Santos, GS Deepe, BS Klein	Cell Host & Microbe	2016
The pro‐fibrotic role of dipeptidyl peptidase 4 in carbon tetrachloride‐induced experimental liver injury XM Wang, LE Holz, S Chowdhury, SP Cordoba, KA Evans, MG Gall, AJ de Ribeiro, YZ Zheng, MT Levy, DM Yu, TW Yao, N Polak, CJ Jolly, P Bertolino, GW McCaughan, MD Gorrell	Immunology and Cell Biology	2016
Alanine aminotransferase, HCV RNA levels and pro-inflammatory and pro-fibrogenic cytokines/chemokines during acute hepatitis C virus infection B Hajarizadeh, FM Lamoury, JJ Feld, J Amin, E Keoshkerian, GV Matthews, M Hellard, GJ Dore, AR Lloyd, J Grebely, TL Applegate	Virology Journal	2016
STAT2 Is Required for TLR-Induced Murine Dendritic Cell Activation and Cross-Presentation J Xu, MH Lee, M Chakhtoura, BL Green, KP Kotredes, RW Chain, U Sriram, AM Gamero, S Gallucci	Journal of immunology (Baltimore, Md. : 1950)	2016
Dipeptidyl Peptidase 4 Distribution in the Human Respiratory Tract DK Meyerholz, AM Lambertz, PB McCray	The American Journal of Pathology	2016
Intratumoral interferon-gamma increases chemokine production but fails to increase T cell infiltration of human melanoma metastases IS Mauldin, NA Wages, AM Stowman, E Wang, ME Smolkin, WC Olson, DH Deacon, KT Smith, NV Galeassi, KA ChianeseBullock, LT Dengel, FM Marincola, GR Petroni, DW Mullins, CL Slingluff	Cancer Immunology, Immunotherapy	2016
Acute Ischemic Stroke Severity, Progression, and Outcome Relate to Changes in Dipeptidyl Peptidase IV and Fibroblast Activation Protein Activity L Baerts, R Brouns, K Kehoe, R Verkerk, S Engelborghs, PP de Deyn, D Hendriks, ID Meester	Translational Stroke Research	2016
Analysis of peripheral blood dendritic cells as a non-invasive tool in the follow-up of patients with chronic hepatitis C A Crosignani	World journal of gastroenterology : WJG	2016
Regulation of Chemokine Activity – A Focus on the Role of Dipeptidyl Peptidase IV/CD26 M Metzemaekers, JV Damme, A Mortier, P Proost	Frontiers in immunology	2016
Cytoplasm-Translocated Ku70/80 Complex Sensing of HBV DNA Induces Hepatitis-Associated Chemokine Secretion Y Li, Y Wu, X Zheng, J Cong, Y Liu, J Li, R Sun, ZG Tian, HM Wei	Frontiers in immunology	2016
Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy RB da Silva, ME Laird, N Yatim, L Fiette, MA Ingersoll, ML Albert	Nature Immunology	2015
Inhibition of MAP kinase/NF-kB mediated signaling and attenuation of lipopolysaccharide induced severe sepsis by cerium oxide nanoparticles V Selvaraj, N Nepal, S Rogers, ND Manne, R Arvapalli, KM Rice, S Asano, E Fankhanel, JJ Ma, T Shokuhfar, M Maheshwari, ER Blough	Biomaterials	2015
Dynamic Changes of Post-Translationally Modified Forms of CXCL10 and Soluble DPP4 in HCV Subjects Receiving Interferon-Free Therapy EG Meissner, J Decalf, A Casrouge, H Masur, S Kottilil, ML Albert, D Duffy, SJ Polyak	PloS one	2015
The Dipeptidyl Peptidase Family, Prolyl Oligopeptidase, and Prolyl Carboxypeptidase in the Immune System and Inflammatory Disease, Including Atherosclerosis Y Waumans, L Baerts, K Kehoe, AM Lambeir, ID Meester	Frontiers in immunology	2015
Blood or Urine IP-10 Cannot Discriminate between Active Tuberculosis and Respiratory Diseases Different from Tuberculosis in Children L Petrone, A Cannas, F Aloi, M Nsubuga, J Sserumkuma, RA Nazziwa, L Jugheli, T Lukindo, E Girardi, K Reither, D Goletti	BioMed Research International	2015
High MIG (CXCL9) plasma levels favours response to peginterferon and ribavirin in HCV-infected patients regardless of DPP4 activity S Johansson, W Talloen, M Tuefferd, J Darling, G Fanning, MW Fried, J Aerssens	Liver International	2015
Association between CXCL10 and DPP4 Gene Polymorphisms and a Complementary Role for Unfavorable IL28B Genotype in Prediction of Treatment Response in Thai Patients with Chronic Hepatitis C Virus Infection K Thanapirom, S Suksawatamnuay, W Sukeepaisarnjaroen, P Tangkijvanich, S Treeprasertsuk, P Thaimai, R Wasitthankasem, Y Poovorawan, P Komolmit, CH Liu	PloS one	2015
The correlation between pretreatment cytokine expression patterns in peripheral blood mononuclear cells with chronic hepatitis c outcome J Jabłońska, T Pawłowski, T Laskus, M Zalewska, M Inglot, S Osowska, K Perlejewski, I Bukowska-Ośko, KC Cortes, A Pawełczyk, P Ząbek, M Radkowski	BMC Infectious Diseases	2015
Harnessing Mechanistic Knowledge on Beneficial Versus Deleterious IFN-I Effects to Design Innovative Immunotherapies Targeting Cytokine Activity to Specific Cell Types E Tomasello, E Pollet, TP Manh, G UzÃ©, M Dalod	Frontiers in immunology	2014
Quantitation of fibroblast activation protein (FAP)-specific protease activity in mouse, baboon and human fluids and organs FM Keane, TW Yao, S Seelk, MG Gall, S Chowdhury, SE Poplawski, JH Lai, Y Li, W Wu, P Farrell, AJ de Ribeiro, B Osborne, DM Yu, D Seth, K Rahman, P Haber, AK Topaloglu, C Wang, S Thomson, A Hennessy, J Prins, SM Twigg, SV McLennan, GW McCaughan, WW Bachovchin, MD Gorrell	FEBS Open Bio	2014
High STAT1 mRNA levels but not its tyrosine phosphorylation are associated with macrophage infiltration and bad prognosis in breast cancer P Tymoszuk, P Charoentong, H Hackl, R Spilka, E Müller-Holzner, Z Trajanoski, P Obrist, F Revillion, JP Peyrat, H Fiegl, W Doppler	BMC Cancer	2014
Vitamin D levels vary during antiviral treatment but are unable to predict treatment outcome in HCV genotype 1 infected patients G Grammatikos, C Lange, S Susser, S Schwendy, N Dikopoulos, P Buggisch, J Encke, G Teuber, T Goeser, R Thimme, H Klinker, WO Boecher, E Schulte-Frohlinde, M Penna-Martinez, K Badenhoop, S Zeuzem, T Berg, C Sarrazin	PloS one	2014
High IP-10 levels decrease T cell function in HIV-1-infected individuals on ART LA Ramirez, TA Arango, E Thompson, M Naji, P Tebas, JD Boyer	Journal of leukocyte biology	2014
IP-10/CXCL10 induction in human pancreatic cancer stroma influences lymphocytes recruitment and correlates with poor survival Lunardi S, Jamieson NB, Lim SY, Griffiths KL, Carvalho-Gaspar M, Al-Assar O, Yameen S, Carter RC, McKay CJ, Spoletini G, D'Ugo S, Silva MA, Sansom OJ, Janssen KP, Muschel RJ, Brunner TB	Oncotarget	2014
Emerging concepts in immunity to hepatitis C virus infection Hugo Rosen	Journal of Clinical Investigation	2013
International Union of Basic and Clinical Pharmacology. LXXXIX. Update on the Extended Family of Chemokine Receptors and Introducing a New Nomenclature for Atypical Chemokine Receptors F Bachelerie, A Ben-Baruch, AM Burkhardt, C Combadiere, JM Farber, GJ Graham, R Horuk, AH Sparre-Ulrich, M Locati, AD Luster, A Mantovani, K Matsushima, PM Murphy, R Nibbs, H Nomiyama, CA Power, AE Proudfoot, MM Rosenkilde, A Rot, S Sozzani, M Thelen, O Yoshie, A Zlotnik, EH Ohlstein	Pharmacological reviews	2013
Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells B Rehermann	Nature Medicine	2013
Plasma interferon-gamma-inducible protein-10 levels are associated with early, but not sustained virological response during treatment of acute or early chronic hcv infection JJ Feld, J Grebely, GV Matthews, T Applegate, M Hellard, A Sherker, V Cherepanov, K Petoumenos, B Yeung, JM Kaldor, AR Lloyd, GJ Dore	PloS one	2013
Inflammatory Mediator Profiling Reveals Immune Properties of Chemotactic Gradients and Macrophage Mediator Production Inhibition during Thioglycollate Elicited Peritoneal Inflammation D Lam, D Harris, Z Qin	Mediators of Inflammation	2013
Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection J Grebely, JJ Feld, T Applegate, GV Matthews, M Hellard, A Sherker, K Petoumenos, G Zang, I Shaw, B Yeung, J George, S Teutsch, JM Kaldor, V Cherepanov, J Bruneau, NH Shoukry, AR Lloyd, GJ Dore	Hepatology	2013
Independent, parallel pathways to CXCL10 induction in HCV-infected hepatocytes J Brownell, J Wagoner, ES Lovelace, D Thirstrup, I Mohar, W Smith, S Giugliano, K Li, IN Crispe, HR Rosen, SJ Polyak	Journal of Hepatology	2013
Individualized Therapy for Hepatitis C Infection: Focus on the Interleukin-28B Polymorphism in Directing Therapy TH Lee, HL Tillmann, K Patel	Molecular diagnosis & therapy	2013
Impact of soluble CD26 on treatment outcome and hepatitis C virus-specific T cells in chronic hepatitis C virus genotype 1 infection J Söderholm, J Waldenström, G Askarieh, M Pilli, PY Bochud, F Negro, JM Pawlotsky, S Zeuzem, C Ferrari, G Norkrans, R Wejstål, J Westin, AU Neumann, BL Haagmans, M Lindh, G Missale, K Hellstrand, M Lagging	PloS one	2013
Dynamic interplay between CXCL levels in chronic hepatitis C patients treated by interferon AR Zekri, AA Bahnassy, WS Mohamed, HM El-Din, HI Shousha, N Zayed, DH Eldahshan, AO Abdel-Aziz	Virology Journal	2013
Soluble CD26/Dipeptidyl Peptidase IV Enhances the Transcription of IL-6 and TNF-α in THP-1 Cells and Monocytes T Ikeda, E Kumagai, S Iwata, A Yamakawa	PloS one	2013
Characterization of cytomegalovirus disease in solid organ transplant recipients by markers of inflammation in plasma H Rollag, T Ueland, A Asberg, A Hartmann, AG Jardine, A Humar, MD Pescovitz, AA Bignamini, P Aukrust	PloS one	2013
Molecular pathways: hepatitis C virus, CXCL10, and the inflammatory road to liver cancer J Brownell, SJ Polyak	Clinical cancer research	2013
CXC chemokine IP-10: a key actor in liver disease? LJ Chen, J Lv, XY Wen, JQ Niu	Hepatology International	2013
Fungi subvert vaccine T cell priming at the respiratory mucosa by preventing chemokine-induced influx of inflammatory monocytes M Wüthrich, K Ersland, T Sullivan, K Galles, BS Klein	Immunity	2012
West Nile Virus: biology, transmission, and human infection TM Colpitts, MJ Conway, RR Montgomery, E Fikrig	Clinical microbiology reviews	2012
Discrimination of agonist and antagonist forms of CXCL10 in biological samples A Casrouge, A Bisiaux, L Stephen, M Schmolz, J Mapes, C Pfister, S Pol, V Mallet, ML Albert	Clinical & Experimental Immunology	2012
Expression sequence tag library derived from peripheral blood mononuclear cells of the chlorocebus sabaeus N Tchitchek, B Jacquelin, P Wincker, C Dossat, CD Silva, J Weissenbach, A Blancher, M Müller-Trutwin, A Benecke	BMC Genomics	2012
Crosstalk between HIV and hepatitis C virus during co-infection PJ Rider, F Liu	BMC Medicine	2012
Lethal Nipah Virus Infection Induces Rapid Overexpression of CXCL10 C Mathieu, V Guillaume, A Sabine, KC Ong, KT Wong, C Legras-Lachuer, B Horvat	PloS one	2012
The CXCR3(+)CD56Bright Phenotype Characterizes a Distinct NK Cell Subset with Anti-Fibrotic Potential That Shows Dys-Regulated Activity in Hepatitis C M Eisenhardt, A Glässner, B Krämer, C Körner, B Sibbing, P Kokordelis, HD Nischalke, T Sauerbruch, U Spengler, J Nattermann	PloS one	2012
Chemokine CXCL10 at Week 4 of Treatment Predicts Sustained Virological Response in Patients with Chronic Hepatitis C I Kurelac, SZ Lepej, I Grlgic, L Gorenec, N Papic, D Dusek, B Barsic, A Vince	Journal of Interferon & Cytokine Research	2012
IL28B Polymorphisms as a Pretreatment Predictor of Response to HCV Treatment CT Berger, AY Kim	Infectious Disease Clinics of North America	2012
dsRNA-Dependent Protein Kinase PKR and its Role in Stress, Signaling and HCV Infection S Dabo, E Meurs	Viruses	2012
IP-10 can be measured in dried plasma spots in patients with chronic hepatitis C infection M Ruhwald, ES Andersen, PB Christensen, BK Moessner, N Weis	PloS one	2012
CD44 participates in IP-10 induction in cells in which hepatitis C virus RNA is replicating, through an interaction with Toll-like receptor 2 and hyaluronan T Abe, T Fukuhara, X Wen, A Ninomiya, K Moriishi, Y Maehara, O Takeuchi, T Kawai, S Akira, Y Matsuura	Journal of virology	2012
Detection of host immune responses in acute phase sera of spontaneous resolution versus persistent hepatitis C virus infection S Selvarajah, S Keating, J Heitman, K Lu, G Simmons, PJ Norris, E Operskalski, JW Mosley, MP Busch	Journal of General Virology	2012
Delayed Induction, Not Impaired Recruitment of Specific CD8+ T Cells, Causes the Late Onset of Acute Hepatitis C EC Shin, SH Park, M Demino, M Nascimbeni, K Mihalik, M Major, NS Veerapu, T Heller, SM Feinstone, CM Rice, B Rehermann	Gastroenterology	2011
Clinical Implications of Chemokines in Acute and Chronic Hepatitis C Virus Infection W Kang, EC Shin	Yonsei Medical Journal	2011
Detection and Quantification of Citrullinated Chemokines EA Moelants, JV Damme, P Proost	PloS one	2011
Pharmacogenomics: Playing the odds A Maxmen	Nature	2011
Chemokine antagonism in chronic hepatitis C virus infection Lynn Dustin, Edgar D. Charles	Journal of Clinical Investigation	2010

Advertisement